Study Finds Dupilumab Improves Skin Barrier Function in Children with Atopic Dermatitis

A recent study published in the Annals of Allergy, Asthma & Immunology, led by researchers at National Jewish Health, demonstrates that dupilumab effectively restores skin barrier function and reduces inflammation in children aged 6 to 11 with moderate-to-severe atopic dermatitis (eczema). The study utilized advanced, noninvasive techniques revealing improvements not only in visible eczema lesions but also in skin areas that appeared clinically unaffected, underscoring the systemic nature of the disease.

Senior author Donald Leung, MD, Ph.D., director of the Food Allergy & Asthma Program at National Jewish Health, noted, "Atopic dermatitis is not just a surface rash. It is a chronic inflammatory disease driven by immune dysfunction and a compromised skin barrier. Our study demonstrates that dupilumab helps normalize the skin barrier in children, including areas of skin that appear clinically unaffected. These findings suggest we may be addressing the underlying disease process, not just treating symptoms."

The researchers assessed skin barrier function using transepidermal water loss and optical coherence tomography—a noninvasive imaging technique that measures epidermal thickness. They found that children with atopic dermatitis exhibited notably higher transepidermal water loss and thicker epidermis in both lesional and non-lesional skin compared to healthy controls, indicating widespread barrier dysfunction and inflammation.

Dr. Leung added, "These objective, noninvasive tools allowed us to see that dupilumab not only improves what we can observe clinically but also repairs deeper structural and functional abnormalities in the skin. Repairing the skin barrier early in life may have important implications for preventing progression to other allergic conditions. Childhood represents a critical window of opportunity when the immune system is still highly adaptable."

The study also noted that dupilumab was generally well tolerated, with no serious or severe adverse events reported that would require treatment discontinuation.